RxDoctor Payments Data

Alan Maloon

Neuromusculoskeletal Medicine & OMM · Roswell, GANPI 1093808057

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $66,725 of the $73,564 with a category attached, or 90.7%. 39 manufacturers reported payments, led by AbbVie at 56.1% of the total. Reporting peaked in 2020 at $31,454 and has fallen 99.9% since, to $34 in 2024.

$73,564in general payments, 2019–2025

Across 409 payments — averaging $179.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • Lilly USA, LLC$25K
  • Biohaven Pharmaceuticals, Inc.$3K
  • Supernus Pharmaceuticals, Inc.$1K
  • UCB, Inc.$410
  • Teva Pharmaceuticals USA, Inc.$321
  • plus $3K from 33 others

What the payments were for

  • Speaking & faculty fees$66,72591%
  • Grants$440%
  • Travel & lodging$7541%
  • Food & beverage$5,7878%
  • Education$2540%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromusculoskeletal medicine & omm providers in Georgiato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amitriptyline Hcl12$85

Paid to pharmacies, not to this prescriber.

Other neuromusculoskeletal medicine & omm in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →